The Associated Press; 50 Rockefeller Plaza, New York, NY 10020 - Monday, September 29, 1997; 1:34 p.m. EDT
Daniel Q. Haney, AP Medical Editor

The disappointing reports suggest the tough virus is coming back after being knocked briefly into submission, just as many experts feared it would.

"Over the past year, we had a honeymoon period," said Dr. Steven Deeks. "The epidemic will likely split in two, and for half the people we will need new therapeutic options."

Deeks presented data from the University of California at San Francisco's large public AIDS clinic at San Francisco General Hospital.

Prescriptions of so-called three-drug cocktails -- two older AIDS drugs plus one of the new class of medicines called protease inhibitors -- have clearly revolutionized AIDS care. In many places, more than 90 percent of AIDS patients are taking these combinations, and typically people start on them as soon as they learn they are infected, even before they get sick.

Patients whose disease-fighting T cells were ravaged by HIV have gotten out of bed, regained normal lives and even gone back to work. However, many worried from the start that the virus would eventually grow resistant to the protease inhibitors and resume its insidious destruction.

The latest data, presented Monday at an infectious disease conference sponsored by the American Society of Microbiology, suggests this is indeed happening regularly.

Deeks and colleagues reviewed the records of 136 HIV-infected people who started on protease inhibitors in March 1996, when Crixivan and Norvir, the first two powerful protease inhibitors, came on the market.

Most patients responded dramatically. Their virus levels dropped so low they could not be found on standard tests. But since then, the virus has returned to detectable levels in 53 percent.

Although this is ominous, no one knows exactly what it means.

"All of our 'failures' are clinically feeling very well," said Deets. "It's very important to understand we have no idea of the prognosis of people who have resistant virus."

Deets said other large AIDS clinics are having similar experiences, although his is the first to present the data publicly.

"There is a whole mixture of explanations" for the failures, said Dr. David Ho of the Aaron Diamond AIDS Research Center in New York City.

Ho said that for people who had relatively low virus levels when they started taking the drugs and had not used other AIDS medicines, failure almost always means they did not take their pills on schedule. Even missing a few doses can ruin the treatment.

"Compliance is absolutely critical," Deets said. "When we say compliance, we mean rigid adherence to over 20 pills a day."

Also at high risk of failure are those who were on other AIDS drugs before starting protease inhibitors or whose T cell counts were very low.

Deets said his data are far different from the carefully controlled drug experiments sponsored by pharmaceutical companies to demonstrate the medicines' potential. These studies show far more encouraging results.

Among the longest-running of these is a study of 28 patients who have been taking Crixivan, AZT and 3TC. Dr. Roy Gulick of New York University said Monday that after almost two years, the virus is still undetectable in 22 of them, or 79 percent.

Deets said real-world experience is not as promising as the trials because patients in the studies are less sick to start with and more highly motivated to scrupulously follow their drug regimens.

Also presented Monday was the first large study of the use of protease inhibitors in children. Just over half appeared to be responding well after three months of therapy.

Copyright 1997/The Associated Press. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, The Associated Press, 50 Rockefeller Plaza, New York, NY 10020.
970929
AP970920

Copyright © 1997 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .